09.06.2014 18:00:00
|
VEXIM Launches New Generation SpineJack® Device during SFCR Congress in Paris
Regulatory News:
VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces the official launch of the SpineJack® New Generation during the Société Française de Chirurgie Rachidienne (SFCR, the French spine surgery society) congress held in Paris from June 5 to 7, 2014.
Backed by its experience with more than 10,000 implants, Vexim has implemented improvements in its SpineJack® system that have simplified and thereby reduced the surgical stages and improved the fluidity of the procedure for surgeons and radiologists. This more comprehensive and accurate SpineJack® implant kit better meets the requirements of spine surgery experts.
These major improvements have also contributed to optimizing the manufacturing processes, thus positively impacting VEXIM’s operating profitability.
Dr. Christian Vasile, orthopedic surgeon at Chambéry hospital, commented: "This new generation SpinkeJack® enables us to reduce the operating time in our minimally invasive back interventions, potentially allowing for faster recovery of patients’ mobility once their vertebral fractures have been treated.”
Vincent Gardès, CEO of VEXIM, added: "In launching the new SpineJack® system, we responded quickly to demands from the clinical community and the specific requirements of surgeons. Indeed, this series of major innovations are a direct result of the feedback received from SpineJack® users and will contribute to improving the surgical treatment of Vertebral Compression Fractures.”
***
About VEXIM, the innovative back microsurgery specialist
Based
in Balma, near Toulouse (France), VEXIM is a medical device company
created in February 2006. The Company has specialized in the creation
and marketing of mini-invasive solutions for treating traumatic spinal
pathologies. Benefitting from the financial support of its longstanding
shareholders, Truffle Capital1 and Banexi Venture, and from
OSEO public subsidies, VEXIM has designed and developed the SpineJack®,
a unique implant capable of repairing a fractured vertebra and restoring
the balance of the spinal column. The Company currently has 57 staff. It
has its own sales teams in France, Germany, Italy, Spain, Switzerland
and the United Kingdom, as well as distributors notably in Argentina,
India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama and in the
following countries where the product is currently being registered:
Mexico, Brazil, Venezuela, Ecuador and Peru. VEXIM has been listed on
NYSE Alternext Paris since May 3, 2012.
For further information,
please go to www.vexim.com
SpineJack®2, a revolutionary implant for treating
Vertebral Compression Fractures
The revolutionary aspect of the
SpineJack® lies in its ability to restore a fractured vertebra to its
original shape, restore the spinal column’s optimal anatomy and thus
remove pain and enable the patient to recover their functional
capabilities. Specialized instruments and guided by X-ray allow the
implants into the vertebra to be carried out by mini-invasive surgery in
approximately 30 minutes enabling the patient to be discharged shortly
after surgery. The SpineJack® range consists of three titanium implants
with three different diameters, thus covering 95% of vertebral
compression fractures and all patient morphologies. SpineJack®
technology benefits from the support of international scientific experts
in the field of spine surgery and worldwide patent protection until 2029.
- Name: VEXIM
- ISIN code: FR0011072602
- Ticker: ALVXM
1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
2 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Veximmehr Nachrichten
Keine Nachrichten verfügbar. |